Topics:

Rheumatoid Arthritis

Rheumatology Apps Not Ready for Prime Time. But ....

Experts and critics say the mobile apps designed for rheumatologists and their patients aren't good enough yet to be clinically useful. But there are reasons why you may have to learn about them anyway ...

Rheumatoid Arthritis

medication risks

When it comes to discussing medication risks, a new study shows, rheumatologists and their patients are speaking different languages. The article reveals how doctors may be sending messages they don't intend.

retinopathy

About half of patients taking hydroxychloroquine, which is used for lupus and rheuamtoid arthritis, aren't tested in time for its blinding effects on the retina, says a review. There are simple ways to use the drug safely.

Articles in two different internal medicine journals last week discussed when and how to use opioids for rheumatologic pain, despite their hazards and limitations.

The JAK1 and JAK2 inhibitor baricitinib has shown significant results in a second Phase 3 trial for rheumatoid arthritis.

prior authorization

Prior authorizations have begun to spread pandemic-like from high-cost biologics to treatments used routinely in rheumatology. The time burden on rheumatologists is insupportable, contends the author, who says it's time to take action.

Two biosimilars for the TNF inhibitor infliximab are now licensed and distributed in Europe. A German rheumatologist wonders what difference the option to prescribe Inflektra and Remsima will make, if any.

FDA boxed warnings about hepatitis B virus (HBV) reactivation risk relate only to ofatumumab and rituximab. Eminent hepatologists say everyone destined for immunosuppression should be tested for HBV first.

Pages

Subscribe to Rheumatoid Arthritis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.